Revance Therapeutics, a clinical stage biotechnology company based in Nashville, develops novel botulinum toxin products, including DAXXIFY and the RHA Collection of dermal fillers. The company partners with Viatris and Fosun for biosimilar development and commercialization in China.
RVNC has been in the news recently: A class action lawsuit has been initiated against Revance Therapeutics, Inc. for allegedly misleading investors during the period from February 29 to December 6, 2024, which coincided with a significant drop in stock price. The lawsuit follows a 20.7% decline in the company's stock price to $3.03 after an amendment to a merger agreement and associated false statements.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
